Subgroup Analyses Show Depth of Everolimus Benefit in BOLERO-2 – OncLive
OncLiveSubgroup Analyses Show Depth of Everolimus Benefit in BOLERO-2OncLiveNew analyses of the BOLERO-2 trial found that everolimus and exemestane produced significantly longer progression-free survival (PFS) than placebo and exemestane in several pre…
